- Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients -
- Safety and response data from dose escalation cohorts of the SURPASS trial to be presented at SITC -
- Durability of response data from patients with synovial sarcoma from the Phase 1 ADP-A2M4 trial to be presented at CTOS -
- Virtual Investor Day planned for November 20, 2020 -
- Financial guidance confirmed: funded into 2022 -
- Conference call to be held today at 8:00 a.m. EST (1:00 p.m. GMT) -
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, today reported financial results and provided a business update for the third quarter ended September 30, 2020.
“Later this month, we will present data at SITC and CTOS. Data to be presented at SITC from the dose escalation cohorts of our SURPASS trial confirm that ADP-A2M4CD8 is a highly active agent across a range of tumors. At CTOS, we will present data regarding the durability of responses in synovial sarcoma, which support our ambition to market ADP‑A2M4 in 2022. And finally, at our Investor Day, I will lay out our broader strategy including the opportunity we see for our late-stage pipeline,” said Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer. “Recruitment into our clinical trials has been steadily recovering following the first wave of COVID-19 and projected patient numbers currently look good for the remainder of this year and into 2021.”
PLANNED MILESTONES Q4 2020
- Four posters to be presented at the virtual SITC meeting (November 9-14)
- Poster entitled “Initial safety, efficacy, and product attributes from the SURPASS trial with ADP‑A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor” with an update on the dose escalation cohorts (6 patients in total)
- Poster entitled “Inhibition of AKT signaling during expansion of TCR-Engineered T-Cells from patient leukocyte material generates SPEAR T-Cells with enhanced functional potential in vitro” with data indicating that AKT inhibition during manufacture of SPEAR T-cells results in a more consistent expansion and phenotype of the final product
- Two posters about the previously terminated ADP-A2M10 Phase 1 program: one for the lung cancer trial, and one for the triple tumor trial in melanoma, urothelial, and head & neck cancers
- Durability of response data from patients with synovial sarcoma from the ADP-A2M4 Phase 1 trial to be presented in an oral presentation at the virtual CTOS conference (“Immunotherapy in Sarcoma” session on November 19, 2020 from 9 a.m. to 10 a.m. EST)
- Investor Day to be held on November 20, 2020
- As the management of COVID-19 at clinical sites continues to evolve, there has been an increase in recruitment and enrollment during the latter part of Q3 and into Q4 for all ongoing clinical trials
- SPEARHEAD-1 is recruiting well and remains on target to complete enrollment in the first half of 2021
- On track to start a Phase 2 trial with ADP-A2M4CD8 in gastroesophageal cancers (gastric, esophageal, and esophagogastric junction) in the first half of 2021
- Data update from the Phase 1 ADP-A2AFP trial presented in an oral presentation and poster, at the International Liver Congress, confirmed safety profile and demonstrated potential benefit for patients with hepatocellular carcinoma. Four patients were treated with ~5 billion or more transduced cells with best responses of one complete response, one patient with stable disease, and two patients with progressive disease.
- Presented SPEARHEAD-2 trial-in-progress poster at ESMO summarizing design for this first combination clinical trial with ADP-A2M4 and pembrolizumab
Financial Results for the three and nine month periods ended September 30, 2020
- Cash / liquidity position: As of September 30, 2020, Adaptimmune had cash and cash equivalents of $78.5 million and Total Liquidity1 of $399.9 million.
- Revenue: Revenue for the three and nine months ended September 30, 2020 was $1.2 million and $2.5 million, respectively, compared to $0.2 million and $0.4 million for the same periods in 2019. Revenue increased due to the commencement of development activity under the Astellas Collaboration Agreement and increased development activity under the GSK Collaboration and License Agreement.
- Research and development (R&D) expenses: R&D expenses for the three and nine months ended September 30, 2020 were $24.1 million and $65.8 million, respectively, compared to $29.6 million and $77.1 million for the same periods in 2019. R&D expenses were higher in the three and nine months ended September 30, 2019 due to recognition of accrued purchase commitment expenses related to the supply of the Dynabeads® CD3/CD28 technology of $5.0 million and in-process research and development as a result of entering into a collaboration agreement with Noile-Immune Biotech, Inc. in August 2019. The nine-month period ended September 30, 2019 also included $2.0 million of in-process research and development as a result of entering into a collaboration agreement with Alpine Immune Sciences, Inc. in May 2019.
- General and administrative (G&A) expenses: G&A expenses for the three and nine months ended September 30, 2020 were $13.0 million and $32.6 million, respectively, compared to $10.7 million and $32.7 million for the same periods in 2019. The increase in the three months ended September 30, 2020 was primarily driven by an increase in professional fees, investment in our IT systems, and costs associated with the buildout of our commercial capabilities.
- Net loss: Net loss attributable to holders of the Company’s ordinary shares for the three and nine months ended September 30, 2020 was $35.4 million and $93.5 million, respectively, and $(0.04) and $(0.11) per ordinary share, respectively, compared to $39.3 million and $107.8 million and $(0.06) and $(0.17) per ordinary share for the same periods in 2019.
The Company believes that its existing cash, cash equivalents and marketable securities will fund the Company’s current operations into 2022, as further detailed in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2020, to be filed with the Securities and Exchange Commission following this earnings release.
Conference Call and Webcast Information
The Company will host a live teleconference at 8:00 a.m. EST (1:00 p.m. GMT) today, November 5, 2020. The live webcast of the conference call will be available in the investor section of Adaptimmune’s corporate website at www.adaptimmune.com. An archive will be available after the call at the same address. To participate in the live conference call, please dial (833) 652-5917 (U.S. or Canada) or +1 (430) 775-1624 (International). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (6183339).
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the SEC on August 6, 2020, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Total Liquidity (a non-GAAP financial measure)
Total Liquidity (a non-GAAP financial measure) is the total of cash and cash equivalents and marketable securities. Each of these components appears separately in the condensed consolidated balance sheet. The U.S. GAAP financial measure most directly comparable to Total Liquidity is cash and cash equivalents as reported in the condensed consolidated financial statements, which reconciles to Total Liquidity as follows (in millions):
|September 30,||December 31,|
|Cash and cash equivalents||$||78.5||50.4|
|Marketable securities – available-for-sale debt securities||321.4||39.1|
The Company believes that the presentation of Total Liquidity provides useful information to investors because management reviews Total Liquidity as part of its management of overall liquidity, financial flexibility, capital structure and leverage.
Condensed Consolidated Statement of Operations
(unaudited, in thousands, except per share data)
|Three months ended||Nine months ended|
|September 30,||September 30,|
|Research and development (including losses accrued on firm purchase commitments of $0, $5,000, $0 and $5,000)||(24,067||)||(29,617||)||(65,791||)||(77,147||)|
|General and administrative||(13,001||)||(10,741||)||(32,557||)||(32,662||)|
|Total operating expenses||(37,068||)||(40,358||)||(98,348||)||(109,809||)|
|Other (expense) income, net||(1,689||)||291||(1,501||)||(556||)|
|Loss before income taxes||(35,417||)||(39,215||)||(93,369||)||(107,647||)|
|Net loss attributable to ordinary shareholders||$||(35,432||)||$||(39,302||)||$||(93,479||)||$||(107,801||)|
|Net loss per ordinary share|
|Basic and diluted||$||(0.04||)||$||(0.06||)||$||(0.11||)||$||(0.17||)|
|Weighted average shares outstanding:|
|Basic and diluted||928,022,057||630,866,800||829,973,177||629,403,293|
Condensed Consolidated Balance Sheets
(unaudited, in thousands, except share data)
|September 30,||December 31,|
|Cash and cash equivalents||$||78,466||$||50,412|
|Marketable securities - available-for-sale debt securities||321,442||39,130|
|Other current assets and prepaid expenses (including current portion of |
|Total current assets||426,733||120,489|
|Operating lease right-of-use assets, net of accumulated amortization||18,775||20,789|
|Property, plant and equipment, net of accumulated depreciation of $28,503 (2019: $23,649)||26,943||31,068|
|Intangibles, net of accumulated amortization||1,970||2,198|
|Liabilities and stockholders’ equity|
|Operating lease liabilities, current||2,619||2,493|
|Accrued expenses and other accrued liabilities||24,615||23,363|
|Deferred revenue, current||3,635||2,128|
|Total current liabilities||34,899||34,341|
|Operating lease liabilities, non-current||21,090||22,966|
|Deferred revenue, non-current||46,212||—|
|Other liabilities, non-current||615||598|
|Common stock - Ordinary shares par value £0.001, 1,038,249,630 authorized and 928,525,410 issued and outstanding (2019: 785,857,300 authorized and 631,003,568 issued and outstanding)||1,325||943|
|Additional paid in capital||932,518||585,623|
|Accumulated other comprehensive loss||(8,494||)||(7,264||)|
|Total stockholders' equity||376,206||123,638|
|Total liabilities and stockholders’ equity||$||479,022||$||181,543|
Condensed Consolidated Cash Flow Statement
(unaudited, in thousands)
|Nine months ended|
|Cash flows from operating activities|
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Share-based compensation expense||7,352||8,495|
|Unrealized foreign exchange (gains) losses||(1,102||)||522|
|Changes in operating assets and liabilities:|
|Decrease (increase) in receivables and other operating assets||3,345||(20,075||)|
|Decrease in non-current operating assets||2,291||1,468|
|(Decrease) increase in payables and other current liabilities||(117||)||8,879|
|Increase in deferred revenue||48,649||2,824|
|Net cash used in operating activities||(24,375||)||(99,979||)|
|Cash flows from investing activities|
|Acquisition of property, plant and equipment||(1,174||)||(1,425||)|
|Acquisition of intangibles||(496||)||(1,036||)|
|Maturity or redemption of marketable securities||78,915||92,803|
|Investment in marketable securities||(363,777||)||(19,080||)|
|Net cash (used in) provided by investing activities||(286,532||)||71,262|
|Cash flows from financing activities|
|Proceeds from issuance of common stock, net of issuance costs||334,388||—|
|Proceeds from exercise of stock options||5,541||366|
|Net cash provided by financing activities||339,929||366|
|Effect of currency exchange rate changes on cash, cash equivalents and |
|Net increase (decrease) in cash, cash equivalents and restricted cash||27,999||(28,749||)|
|Cash, cash equivalents and restricted cash at start of period||54,908||72,476|
|Cash, cash equivalents and restricted cash at end of period||$||82,907||$||43,727|
Juli P. Miller, Ph.D. — Senior Director, Investor Relations
T: +1 215 825 9310
M: +1 215 460 8920
1 Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below.